Source: FirstWord Pharma

Affinivax: Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine

- Preclinical data show synergistic protective effect of anti-protein and anti-polysaccharide antibodies in a highly virulent model of serotype 3 invasive pneumococcal disease - - Presentation a...

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Steven Brugger's photo - President & CEO of Affinivax

President & CEO

Steven Brugger

CEO Approval Rating

86/100

Read more